IMV Stock Forecast, Price & News

+0.08 (+3.81 %)
(As of 08/5/2021 12:12 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume60,311 shs
Average Volume142,005 shs
Market CapitalizationC$178.94 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive IMV News and Ratings via Email

Sign-up to receive the latest news and ratings for IMV and its competitors with MarketBeat's FREE daily newsletter.

IMV logo

About IMV

IMV Inc., a biopharmaceutical company, focuses on the development of cancer immunotherapies and vaccines against infectious diseases using its DPX delivery technology platform. The company's lead drug candidate includes maveropepimut-S (DPX-Survivac), a T cell therapy, which is in three Phase II clinical trials across 6 different cancer indications with and without Merck's Keytruda; and Phase II clinical trials for the treatment of ovarian cancer, and recurrent and refractory diffuse large B cell lymphoma. It is also developing DPX-COVID-19, a second-generation vaccine against severe acute respiratory syndrome coronavirus 2; and DPX-RSV, a vaccine candidate, which has completed Phase I clinical trials for the treatment of respiratory syncytial virus strain A, as well as DPX-SurMAGE for the treatment of bladder cancer and DPX-BRAF to treat melanoma patients. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.56 out of 5 stars

Analyst Opinion: 3.0Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

IMV (TSE:IMV) Frequently Asked Questions

Is IMV a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IMV in the last year. There are currently 4 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" IMV stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IMV, but not buy additional shares or sell existing shares.
View analyst ratings for IMV
or view top-rated stocks.

What stocks does MarketBeat like better than IMV?

Wall Street analysts have given IMV a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but IMV wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is IMV's next earnings date?

IMV is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021.
View our earnings forecast for IMV

How were IMV's earnings last quarter?

IMV Inc. (TSE:IMV) announced its earnings results on Wednesday, May, 12th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.03. The business had revenue of $0.09 million for the quarter.
View IMV's earnings history

How has IMV's stock been impacted by Coronavirus (COVID-19)?

IMV's stock was trading at C$3.39 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, IMV shares have decreased by 37.2% and is now trading at C$2.13.
View which stocks have been most impacted by COVID-19

What price target have analysts set for IMV?

4 analysts have issued 1 year price objectives for IMV's shares. Their forecasts range from C$2.50 to C$4.25. On average, they anticipate IMV's share price to reach C$3.67 in the next twelve months. This suggests a possible upside of 72.1% from the stock's current price.
View analysts' price targets for IMV
or view top-rated stocks among Wall Street analysts.

Who are IMV's key executives?

IMV's management team includes the following people:
  • Mr. Frederic Ors M.B.A., B.Sc., M.A., CEO & Director (Age 47, Pay $771.72k)
  • Mr. Pierre Labbé C.A., C.P.A., CPA, CA, ICD, Chief Financial Officer (Age 56, Pay $534.87k)
  • Mr. Andrew Hall M.Sc., Chief Bus. Officer
  • Dr. Jeremy R. Graff, Chief Scientific Officer
  • Mr. Marc Jasmin CPA, CMA, Sr. Director of Investor Relations
  • Ms. Annie Tanguay B.Sc., Sr. VP of Quality & Compliance
  • Delphine Davan, Director of Communications
  • Ms. Linda Barabe M.B.A., VP of HR
  • Dr. Marianne Stanford, VP of R&D

Who are some of IMV's key competitors?

What other stocks do shareholders of IMV own?

What is IMV's stock symbol?

IMV trades on the Toronto Stock Exchange (TSX) under the ticker symbol "IMV."

How do I buy shares of IMV?

Shares of IMV and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is IMV's stock price today?

One share of IMV stock can currently be purchased for approximately C$2.13.

How much money does IMV make?

IMV has a market capitalization of C$174.83 million and generates C$2,385.00 in revenue each year.

How many employees does IMV have?

IMV employs 77 workers across the globe.

What is IMV's official website?

The official website for IMV is www.imvaccine.com.

Where are IMV's headquarters?

IMV is headquartered at 1344 Summer Street, Suite 412, HALIFAX, NS B3H 0A8, Canada.

How can I contact IMV?

IMV's mailing address is 1344 Summer Street, Suite 412, HALIFAX, NS B3H 0A8, Canada. The company can be reached via phone at +1-902-4921819.

This page was last updated on 8/5/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.